3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

| More on:
Two lab workers fist pump each other.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares couldn't avoid the broader market sell-off on Monday.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock ended the day down 1.4%, trading for $276.42 apiece.

That sees CSL shares down 7.9% since this time last year, underperforming the 9.9% 12-month gains posted by the ASX 200. Modestly softening those losses for shareholders, the biotech stock also trades on a 1.4% unfranked trailing dividend yield.

With that lacklustre year of performance behind it, here's why these two investing experts are optimistic on the outlook for CSL in 2025 (courtesy of The Bull).

The bullish case for CSL shares

"CSL is a global biotechnology company," said Sequoia Wealth Management's Peter Day, who has a buy recommendation on CSL shares.

He added:

Its medicines treat haemophilia and immune deficiencies. Its vaccines prevent influenza. It provides therapies in iron deficiency and nephrology. CSL provides products to more than 100 countries.

Explaining his optimistic outlook for CSL stock, Day said, "The company has posted a significant increase in revenue during the past three years and delivered earnings growth that's compounding at double-digit rates."

Revenue and earnings growth count as the first reason you may want to consider buying CSL shares today.

As for the second reason, Day said, "CSL was recently trading on a modest and appealing price/earnings ratio, which provides valuation support at current levels."

At Monday's close, CSL was trading at a P/E ratio of approximately 32 times.

Time for a rebound?

Catapult Wealth's Dylan Evans also has a buy recommendation on CSL shares. And he's expecting a rebound for the ASX 200 biotech company after a long stretch of underperformance.

"The share price of this blood products company has been a disappointing performer," he said.

Evans noted that "The shares have fallen from $320.03 on February 3, 2020, to trade at $276.77 on January 30, 2025."

And he said this didn't appear to stack up against the company's financial performance.

Which is the third reason CSL shares look like a good buy today.

According to Evans:

The company generated full year 2024 net profit after tax of $2.75 billion at constant currency, up 25% on the prior corresponding period. CSL is a high-quality defensive stock, anticipating double digit earnings growth in fiscal year 2025 amid trading on a relatively modest earnings multiple.

The patience of long-term investors has certainly been tested, but we expect good returns going forward.

CSL reported its FY 2024 results on 13 August.

Atop growing profits, the company achieved revenue growth of 11% in constant currency to US$14.8 billion.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »